BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2046808)

  • 1. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 5. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D; Fourtounas C; Tsouchnikas J; Barboutis K
    Am J Kidney Dis; 1996 Jul; 28(1):156. PubMed ID: 8712214
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of recombinant erythropoietin on electrolytes and nutrition in end-stage renal disease patients.
    Kaupke CJ; Vaziri ND
    Int J Artif Organs; 1993 Feb; 16(2):59-62. PubMed ID: 8486413
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 8. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 10. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 12. Human recombinant erythropoietin used to treat a cat with anemia caused by chronic renal failure.
    Henry PA
    Can Vet J; 1994 Jun; 35(6):375. PubMed ID: 8069840
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of uremic anemia and new therapeutic prospectives.
    Lamperi S; Carozzi S; Icardi A; Nasini MG; Traverso GB
    Contrib Nephrol; 1989; 69():190-4; discussion 195-6. PubMed ID: 2661141
    [No Abstract]   [Full Text] [Related]  

  • 16. The end stage renal disease program.
    Goodkin DA
    N Engl J Med; 1993 Jul; 329(2):140; author reply 140-1. PubMed ID: 8510703
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
    Adamson JW; Eschbach JW
    Annu Rev Med; 1990; 41():349-60. PubMed ID: 2184735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin use in pregnancy: two cases and a review of the literature.
    Scott LL; Ramin SM; Richey M; Hanson J; Gilstrap LC
    Am J Perinatol; 1995 Jan; 12(1):22-4. PubMed ID: 7710570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.